- Report
- February 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- April 2025
- 150 Pages
Global
From €4430EUR$4,850USD£3,788GBP
- Report
- March 2025
- 150 Pages
Global
From €4430EUR$4,850USD£3,788GBP
- Report
- May 2024
- 185 Pages
Global
From €4110EUR$4,500USD£3,515GBP
- Report
- December 2023
- 145 Pages
Global
From €5434EUR$5,950USD£4,647GBP
- Report
- September 2023
- 236 Pages
Global
From €5434EUR$5,950USD£4,647GBP
- Report
- February 2022
- 180 Pages
Global
From €4064EUR$4,450USD£3,476GBP
- Book
- October 2019
- 720 Pages
Imipenem is an antibiotic used to treat a wide range of bacterial infections. It belongs to a class of antibiotics known as carbapenems, which are used to treat serious infections caused by bacteria that are resistant to other antibiotics. Imipenem is typically used in combination with other antibiotics to treat infections such as pneumonia, urinary tract infections, and skin and soft tissue infections. It is also used to treat infections caused by certain types of bacteria that are resistant to other antibiotics.
Imipenem is available in both oral and intravenous formulations. It is usually administered intravenously in the hospital setting, while oral formulations are available for outpatient use. Imipenem is generally well tolerated, but can cause side effects such as nausea, vomiting, and diarrhea.
Imipenem is a widely used antibiotic and is available from many pharmaceutical companies. Some of the companies that produce imipenem include Merck, Pfizer, GlaxoSmithKline, and AstraZeneca. Show Less Read more